Skip to main content
SpringerLink
Log in

Ovarielles Überstimulationssyndrom

  • Living reference work entry
  • First Online:
Reproduktionsmedizin

Part of the book series: Springer Reference Medizin ((SRM))

  • 257 Accesses

Zusammenfassung

Das ovarielle Überstimulationssyndrom bleibt bis heute ein Risiko in der Kinderwunschtherapie, kann aber in seltenen Fällen auch spontan auftreten. Es gilt für die Praxis, Patientinnen mit erhöhtem Risiko vor Beginn einer Stimulationsbehandlung zu identifizieren (z. B. Patientinnen mit PCOS, hohem AMH-Wert, großer Anzahl antraler Follikel). Innerhalb der Stimulationstherapie können weitere Risikofaktoren identifiziert werden, z. B. hohe Östradiolwerte, >10 Follikel >13 mm. Bei Einsatz des mittlerweile in Deutschland hauptsächlich angewandten Antagonistenprotokolls besteht die Möglichkeit, die finale Oozytenmaturation mittels GnRH-Agonist zu triggern und einen Embryotransfer auf einen unstimulierten Zyklus zu verschieben, denn hCG gilt als ultimativer Trigger eines OHSS insbesondere auch beim Eintritt einer Schwangerschaft in einem hoch stimulierten Zyklus. Die für die Stimulation gewählte Dosis sollte daher abhängig von den Charakteristika der Patientin individuell angepasst werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Abdallah R, Kligman I, Davis O, Rosenwaks Z (2010) Withholding gonadotropins until human chorionic gonadotropin administration. Semin Reprod Med 28:486–492

    Article  CAS  Google Scholar 

  • Al-Ramahi M, Leader A, Claman P, Spence J (1997) A novel approach to the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod 12:2614–2616

    Article  CAS  Google Scholar 

  • Álvarez C, Alonso-Muriel I, García G, Crespo J, Bellver J, Simón C, Pellicer A (2007a) Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 22:3210–3214. https://doi.org/10.1093/humrep/dem315

    Article  CAS  PubMed  Google Scholar 

  • Álvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, FernÁndez-SÁnchez M, Simón C, Pellicer A (2007b) Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 92:2931–2937. https://doi.org/10.1210/jc.2007-0409

    Article  CAS  PubMed  Google Scholar 

  • Artini PG, Monti M, Fasciani A, Battaglia C, D’Ambrogio G, Genazzani AR (2002) Vascular endothelial growth factor, interleukin-6 and interleukin-2 in serum and follicular fluid of patients with ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 101:169–174. http://www.sciencedirect.com/science/article/pii/S0301211501005681

    Article  CAS  Google Scholar 

  • Atkinson P, Koch J, Ledger W (2014) GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates. Aust N Z J Obstet Gynaecol 54:581–585

    Article  Google Scholar 

  • Binder H, Griesinger G, Kiesel L (2007) Ovarielles Überstimulationssyndrom. Gynäkologische Endokrinol 5:203–211

    Article  CAS  Google Scholar 

  • Binder H, Flegel W, Emran J, Müller A, Cupisti S, Beckmann M, Eckstein R, Dittrich R, Ringwald J (2008) Blood group A: an overseen risk factor for early-onset ovarian hyperstimulation syndrome? Reprod Biomed Online 17:185–189

    Article  Google Scholar 

  • Bonilla-Musoles F, Raga F, Castillo J, Sanz M, Dolz M, Osborne N (2009) High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome. Clin Exp Obstet Gynecol 36:78–81

    CAS  PubMed  Google Scholar 

  • Brinsden P, Wada I, Tan S, Balen A, Jacobs H (1995) Diagnosis, prevention and management of ovarian hyperstimulation syndrome. BJOG 102:767–772

    Article  CAS  Google Scholar 

  • Budev M, Arroliga A, Falcone T (2005) Ovarian hyperstimulation syndrome. Crit Care Med 33:S301–S306

    Article  Google Scholar 

  • Cerrillo M, Rodríguez S, Mayoral M, Pacheco A, Martínez-Salazar J, Garcia-Velasco JA (2009) Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction. Fertil Steril 91:1526–1528. http://www.sciencedirect.com/science/article/pii/S0015028208038284

    Article  CAS  Google Scholar 

  • Chauhan AR, Prasad M, Chamariya S, Achrekar S, Mahale SD, Mittal K (2015) Novel FSH receptor mutation in a case of spontaneous ovarian hyperstimulation syndrome with successful pregnancy outcome. J Hum Reprod Sci 8:230–233. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691976/

    Article  CAS  Google Scholar 

  • Chen S-U, Chou C-H, Lin C-W, Lee H, Wu J-C, Lu H-F, Chen C-D, Yang Y-S (2010) Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways. Hum Reprod 25:757–767. https://doi.org/10.1093/humrep/dep432

    Article  CAS  PubMed  Google Scholar 

  • Corbett S, Shmorgun D, Claman P (2014) The prevention of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can 36:1024–1033. http://www.sciencedirect.com/science/article/pii/S1701216315304175

    Article  Google Scholar 

  • De Leener A, Montanelli L, Van Durme J, Chae H, Smits G, Vassart G, Costagliola S (2006) Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J Clin Endocrinol Metab 91:555–562. https://doi.org/10.1210/jc.2005-1580

    Article  CAS  PubMed  Google Scholar 

  • Delbaere A, Bergmann PJM, Gervy-Decoster C, Staroukine M, Englert Y (1994) Angiotensin II immunoreactivity is elevated in ascites during severe ovarian hyperstimulation syndrome: implications for pathophysiology and clinical management**Supported by grant 1.5.218.94F from the Fonds National de la Recherche Scientifique (F.N.R.S.). Fertil Steril 62:731–737. http://www.sciencedirect.com/science/article/pii/S0015028216569970

    Article  CAS  Google Scholar 

  • Elchalal U, Schenker J (1997) The pathophysiology of ovarian hyperstimulation syndrome – views and ideas. Hum Reprod 12:1129–1137

    Article  CAS  Google Scholar 

  • Enskog A, Nilsson L, Brännström M (2000) Peripheral blood concentrations of inhibin B are elevated during gonadotrophin stimulation in patients who later develop ovarian OHSS and inhibin A concentrations are elevated after OHSS onset. Hum Reprod 15:532–538

    Article  CAS  Google Scholar 

  • Forman RG, Frydman R, Egan D, Ross C, Barlow DH (1990) Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention**Presented in part at the 6th World Congress on In Vitro Fertilization, Jerusalem, Israel. Fertil Steril 53:502–509. http://www.sciencedirect.com/science/article/pii/S0015028216533482

    Article  CAS  Google Scholar 

  • Gao M-Z, Zhao X-M, Sun Z-G, Hong Y, Zhao L-W, Zhang H-Q (2011) Endocrine gland-derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome in women undergoing controlled ovarian hyperstimulation. Fertil Steril 95:673–678. http://www.sciencedirect.com/science/article/pii/S0015028210026063

    Article  CAS  Google Scholar 

  • Geva E, Lessing JB, Lerner-Geva L, Azem F, Yovel I, Amit A (1997) Elevated levels of interleukin-6 in the follicular fluid at the time of oocyte retrieval for in vitro fertilization may predict the development of early-form ovarian hyperstimulation syndrome. Fertil Steril 68:133–137. http://www.sciencedirect.com/science/article/pii/S0015028297814896

    Article  CAS  Google Scholar 

  • Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E (1989) Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 44:430–440

    Article  CAS  Google Scholar 

  • Griesinger G, Diedrich K, Tarlatzis B, Kolibianakis E (2006) GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 13:628–638

    Article  CAS  Google Scholar 

  • Griesinger G, Binder H, Diedrich K (2008) Neue Ansätze bei der Prävention des ovariellen Überstimulationssyndroms. Gynäkologische Endokrinol 6:165–170

    Article  CAS  Google Scholar 

  • Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S (2011) Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a „freeze-all“ strategy: a prospective multicentric study. Fertil Steril 95:2029–2033.e1. http://www.sciencedirect.com/science/article/pii/S0015028211002421

    Article  CAS  Google Scholar 

  • Haas J, Baum M, Meridor K, Hershko-Klement A, Elizur S, Hourvitz A, Orvieto R, Yinon Y (2018) Is severe OHSS associated with adverse pregnancy outcomes? Evidence from a case-control study. Reprod Biomed Online 29:216–221. https://doi.org/10.1016/j.rbmo.2014.04.015

    Article  Google Scholar 

  • Kerkelä E, Skottman H, Friden B, Bjuresten K, Kere J, Hovatta O (2007) Exclusion of coding-region mutations in luteinizing hormone and follicle-stimulating hormone receptor genes as the cause of ovarian hyperstimulation syndrome. Fertil Steril 87:603–606. https://doi.org/10.1016/j.fertnstert.2006.06.060

    Article  CAS  PubMed  Google Scholar 

  • Kissler S, Neidhardt B, Siebzehnrübl E, Schmitt H, Tschaikowsky K, Wildt L (2001) The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation syndrome: a case report. Eur J Obstet Gynecol Reprod Biol 99:131–134. http://www.sciencedirect.com/science/article/pii/S0301211501003645

    Article  CAS  Google Scholar 

  • Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G (2006) Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 12:651–671. https://doi.org/10.1093/humupd/dml038

    Article  CAS  PubMed  Google Scholar 

  • Kolibianakis EM, Papanikolaou EG, Tournaye H, Camus M, Van Steirteghem AC, Devroey P (2007) Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating horm. Fertil Steril 88:1382–1388. http://www.sciencedirect.com/science/article/pii/S0015028207001100

    Article  CAS  Google Scholar 

  • Kosaka K, Fujiwara H, Yoshioka S, Fujii S (2007) Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome. Hum Reprod 22:1647–1651. https://doi.org/10.1093/humrep/dem042

    Article  PubMed  Google Scholar 

  • Lainas GT, Kolibianakis EM, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas TG, Tarlatzis BC (2013) Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. Hum Reprod 28:1929–1942. https://doi.org/10.1093/humrep/det114

    Article  CAS  PubMed  Google Scholar 

  • Luke B, Brown MB, Morbeck DE, Hudson SB, Coddington CC III, Stern JE (2018) Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome. Fertil Steril 94:1399–1404. https://doi.org/10.1016/j.fertnstert.2009.05.092

    Article  CAS  Google Scholar 

  • Manau D, Fábregues F, Arroyo V, Jiménez W, Vanrell JA, Balasch J (2002) Hemodynamic changes induced by urinary human chorionic gonadotropin and recombinant luteinizing hormone used for inducing final follicular maturation and luteinization. Fertil Steril 78:1261–1267. http://www.sciencedirect.com/science/article/pii/S0015028202043947

    Article  Google Scholar 

  • McClure N, Leya J, Radwanska E, Rawlins R, Haning RJ (2000) Luteal phase support and severe ovarian hyperstimulation syndrome. Hum Reprod 7:758–764

    Article  Google Scholar 

  • McElhinney B, Ardill J, Caldwell C, Lloyd F, McClure N (2002) Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others? Hum Reprod 17:1548–1553

    Article  Google Scholar 

  • Mensah J, Kimmig R, Schmidt M (2010) Ovarielles Überstimulationssyndrom in einer aneuploiden Gravidität. Geburtshilfe Frauenheilkd 70:828–831

    Article  Google Scholar 

  • Morris R, Paulson R (1994) Ovarian derived prorenin-angiotensin cascade in human reproduction. Fertil Steril1 62:1105–1114

    Article  CAS  Google Scholar 

  • Muller P (1962) In: Beclere C (Hrsg) Gonadotrophines en Gynecologie, Bd 137. Masson, Paris

    Google Scholar 

  • Nargund G, Hutchison L, Scaramuzzi R, Campbell S (2007) Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reprod Biomed Online 14:682–685

    Article  CAS  Google Scholar 

  • Navot D, Bergh P, Laufer N (1992) Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 58:249–261

    Article  CAS  Google Scholar 

  • Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marmé D, Breckwoldt M (1995) Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 80:1967–1971. https://doi.org/10.1210/jcem.80.6.7775647

    Article  CAS  PubMed  Google Scholar 

  • Nyboe Andersen A, Nelson SM, Fauser BCJM, García-Velasco JA, Klein BM, Arce J-C (2017) Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril 107:387–396.e4. http://www.sciencedirect.com/science/article/pii/S0015028216629564

    Article  CAS  Google Scholar 

  • Olivennes F (2010) Ovarian hyperstimulation syndrome prevention strategies: individualizing gonadotropin dose. Semin Reprod Med 28:463–467

    Article  CAS  Google Scholar 

  • Orvieto R, Dekel A, Dicker D, Bar-Hava I, Ben-Rafael Z (1995) A severe case of ovarian hyperstimulation syndrome despite the prophylactic administration of intravenous albumin. Fertil Steril 64:860–862. http://www.sciencedirect.com/science/article/pii/S0015028216578674

    Article  CAS  Google Scholar 

  • Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, Devroey P (2005) Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod 20:636–641. https://doi.org/10.1093/humrep/deh638

    Article  PubMed  Google Scholar 

  • Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohí J, Simón C (1999) The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1β, interleukin-6, and vascular endothelial growth factor. Fertil Steril 71:482–489. http://www.sciencedirect.com/science/article/pii/S0015028298004841

    Article  CAS  Google Scholar 

  • Raziel A, Friedler S, Schachter M, Strassburger D, Mordechai E, Ron-El R (2002) Increased early pregnancy loss in IVF patients with severe ovarian hyperstimulation syndrome. Hum Reprod 17:107–110

    Article  Google Scholar 

  • Rizk B (2009) Symposium: update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online 19:14–27

    Article  CAS  Google Scholar 

  • Rizk B, Aboulghar M (1999) Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: Brinsden P et al (Hrsg) A textbook of invitro fertilisation, 2. Aufl. Lancanster, UK, Parthenon Publishing, S 131–155

    Google Scholar 

  • Rollene NL, Amols MH, Hudson SBA, Coddington CC (2009) Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertil Steril 92:1169.e15–1169.e17. http://www.sciencedirect.com/science/article/pii/S0015028209012102

    Article  Google Scholar 

  • Shapiro A, Thomas T, Epstein M (1977) Management of hyperstimulation syndrome. Fertil Steril 28:237–239

    Article  CAS  Google Scholar 

  • Steward RG, Lan L, Shah AA, Yeh JS, Price TM, Goldfarb JM, Muasher SJ (2014) Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril 101:967–973. http://www.sciencedirect.com/science/article/pii/S0015028213034584

    Article  Google Scholar 

  • Tan SL, Child TJ, Cheung AP, Fluker MR, Yuzpe A, Casper R, Leung P, Cadesky K, Davis VJ (2005) A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon®) in women undergoing controlled ovarian hyperstimulation for IVF treatment. J Assist Reprod Genet 22:81–88. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3455475/

    Article  Google Scholar 

  • The European Recombinant LH Study Group (2001) Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 86:2607–2618. https://doi.org/10.1210/jcem.86.6.7599

    Article  Google Scholar 

  • Uchida S, Uchida H, Maruyama T, Kajitani T, Oda H, Miyazaki K, Kagami M, Yoshimura Y (2013) Molecular analysis of a mutated FSH receptor detected in a patient with spontaneous ovarian hyperstimulation syndrome (Luque RM, Hrsg). PLoS One 8:e75478. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772932/

    Article  CAS  Google Scholar 

  • Verit FF, Cetin O, Yildirim O, Keskin S, Yucel O, Yalcinkaya S (2014) Neutrophil to lymphocyte ratio is superior to platelet to lymphocyte ratio as an early predictor of moderate/severe ovarian hyperstimulation syndrome. J Obstet Gynaecol (Lahore) 34:639–643. https://doi.org/10.3109/01443615.2014.920792

    Article  CAS  Google Scholar 

  • Wang T-H, Horng S-G, Chang C-L, Wu H-M, Tsai Y-J, Wang H-S, Soong Y-K (2002) Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 87:3300–3308. https://doi.org/10.1210/jcem.87.7.8651

    Article  CAS  PubMed  Google Scholar 

  • Zalel Y, Katz Z, Caspi B, Ben-Hur H, Dgani R, Insler V (1992) Spontaneous ovarian hyperstimulation syndrome concomitant with spontaneous pregnancy in a woman with polycystic ovary disease. Am J Obstet Gynecol 167:122–124. https://doi.org/10.1016/S0002-9378(11)91642-1

    Article  CAS  PubMed  Google Scholar 

  • Zivi E, Simon A, Laufer N (2010) Ovarian hyperstimulation syndrome: definition, incidience, and classification. Semin Reprod Med 28:441–447

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäres interdisziplinäres Kinderwunschzentrum Düsseldorf, Düsseldorf, Deutschland

    Alexandra Petra Bielfeld, Jan-Steffen Krüssel & Dunja-Maria Baston-Büst

Authors
  1. Alexandra Petra Bielfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan-Steffen Krüssel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dunja-Maria Baston-Büst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandra Petra Bielfeld .

Editor information

Editors and Affiliations

  1. Facharzt-Zentrum für Kinderwunsch, Pränatale Medizin, Endokrinologie und Osteologie Hamburg GmbH, amedes experts, Hamburg, Germany

    Klaus Diedrich

  2. SYNLAB Holding Deutschland GmbH, Augsburg, Hamburg, Germany

    Michael Ludwig

  3. Sektion für gynäkologische Endokrinologie und Reproduktionsmedizin, UNIVERSITÄTSKLINIKUM Schleswig-Holstein – Campus Lübeck, Lübeck, Schleswig-Holstein, Germany

    Georg Griesinger

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Bielfeld, A.P., Krüssel, JS., Baston-Büst, DM. (2019). Ovarielles Überstimulationssyndrom. In: Diedrich, K., Ludwig, M., Griesinger, G. (eds) Reproduktionsmedizin. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-55601-6_32-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-55601-6_32-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-55601-6

  • Online ISBN: 978-3-662-55601-6

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation